.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,521,067

« Back to Dashboard

Details for Patent: 7,521,067

Title:Methods and apparatus for determining formulation orientation of multi-layered pharmaceutical dosage forms
Abstract: Rapid and accurate determination of the formulation orientation of multi-layer capsule-shaped tablets with respect to different internal formulation layers proximate to the opposite narrow and rounded ends of the tablets is required. By including an appropriate color scheme in multi-layer osmotic tablets, detection of the formulation orientation is achieved by detecting the color at a spot location on a side of the tablet corresponding to one or another formulation layer or to one or another interface of two formulation layers depending on the formulation orientation of the tablet.
Inventor(s): Geerke; Johan H (Los Altos, CA), Stone; Steven F. (Saratoga, CA)
Assignee: Alza Corporation (Mountain View, CA)
Filing Date:Jun 02, 1999
Application Number:09/324,343
Claims:1. A method of making a three-layer capsule-shaped tablet comprising: formulating a first layer containing a drug ingredient and a second layer containing a drug ingredient, wherein one of the layers comprises a first colorant; formulating a non-drug ingredient containing third layer comprising a second colorant that is distinguishable from the first colorant or from no color and not containing any drug ingredient; compressing the first, second and third layers into a capsule-shaped osmotic tablet wherein the first layer is located at one end of the capsule-shaped osmotic tablet and the third layer is located at the other end of the capsule-shaped osmotic tablet and the second layer is located between the first layer and the third layer such that the formulation orientation of the tablet can be determined by detecting the color at a spot location on a side of the tablet corresponding to one or another differently-colored layer depending on the formulation orientation of the tablet; and detecting the formulation orientation of the tablet with a color detector directed at a spot location on the side of the tablet.

2. The method of claim 1 wherein the first colorant is light and the second colorant is dark.

3. A method of making a three-layer capsule-shaped tablet comprising: formulating a first layer containing a drug ingredient and not containing any colorant; formulating a second layer containing a drug ingredient and a first colorant, the first colorant being complementary to no color; formulating a third layer containing a second colorant that is distinguishable from the first colorant or from no color and not containing any drug ingredient; compressing the first, second and third layers into a capsule-shaped osmotic tablet the first layer is located at one end of the capsule-shaped osmotic tablet and the third layer is located at the other end of the capsule-shaped osmotic tablet and the second layer is located between the first layer and the third layer such that the formulation orientation of the tablet can be determined by detecting the color at a spot location on a side of the tablet corresponding to one or another differently-colored layer depending on the formulation orientation of the tablet; and detecting the formulation orientation of the tablet with a color detector directed at a spot location in the side of the tablet.

4. The method of claim 1 wherein said second layer comprises a larger concentration of drug ingredient than said first layer.

5. The method of claim 1 wherein said first and second layers comprise methylphenidate chloride.

6. The method of claim 1 wherein said first layer comprises about 9% to about 10% by weight methylphenidate chloride and said second layer comprises about 13% to about 14% by weight methylphenidate chloride.

7. The method of claim 3 wherein said second layer comprises a larger concentration of drug ingredient than said first layer.

8. The method of claim 3 wherein said first and second layers comprise methylphenidate chloride.

9. The method of claim 3 wherein said first layer comprises about 9% to about 10% by weight methylphenidate chloride and said second layer comprises about 13% to about 14% by weight methylphenidate chloride.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc